Citius Pharmaceuticals (CTXR) Announces $20.0 Million Private Placement of Common Stock, Warrants
- Wall St ticks up on megacaps, earnings boost
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Wall St turns higher, gold climbs, oil dips amid economic, geopolitical crosswinds
- US dollar modestly firmer after strong data, Fed comments
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Lithium Americas Corp (LAC) Announces Proposed 55M Share Offering
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
Citius Pharmaceuticals Announces $20.0 Million Private Placement Priced At-the-Market
January 25, 2021 7:00 AM ESTCRANFORD, N.J., Jan. 25, 2021 /PRNewswire/ --Â Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise approximately $20.0 million through the issuance of an aggregate 15,455,960 shares of its common stock and warrants to purchase up to an aggregate of 7,727,980 shares of common stock, at a purchase price of $1.294 per share of common stock and associated warrant in a private placement priced... More